LONDON Feb 6 GlaxoSmithKline, Britain's
biggest drugmaker, renewed its promise to return to growth this
year, after failing to deliver a hoped-for sales and margin
recovery in 2012.
GSK also announced a restructuring of European operations,
drug manufacturing and research, designed to save at least 1
billion pounds ($1.57 billion) annually by 2016, while it placed
its Lucozade and Ribena drinks brands under strategic review.
After putting a number of major drug patent losses behind
it, GSK had originally banked on pulling out of its trough in
2012. In the event, sales were held back by larger-than-expected
drug price cuts in austerity-hit Europe.
Sales in the final quarter of 2012 fell 3 percent to 6.80
billion pounds, generating "core" earnings per share (EPS) up 4
percent at 32.6p pence, the company said on Wednesday.
Analysts, on average, had forecast sales of 6.88 billion
pounds and core EPS, which excludes certain items, of 31.3p,
according to Thomson Reuters I/B/E/S.
Chief Executive Andrew Witty is now looking to a clutch of
new medicines to revive growth, starting with six drugs that
have already been submitted for approval in lung disease,
melanoma, diabetes and HIV/AIDS.
Keenly awaited final-stage Phase III clinical trial results
are also due for two high-risk, high-reward projects in heart
disease and cancer.
That makes 2013 a crucial year for GSK's pipeline, although
the main impact on the sales line will be felt during 2014 and
beyond - assuming that the new medicines live up to
GSK's stock has underperformed in the past year, due to
disappointment at its lack of growth, and it now languishes
second to last among large European drugmakers in terms of
sell-side analysts' ratings, ahead only of AstraZeneca,
according to Thomson Reuters data.